



December 21, 2015

Press release

Mitsubishi Tanabe Pharma Corporation

## **RADICUT<sup>®</sup> inj. 30mg and RADICUT<sup>®</sup> Infusion inj. 30mg An import and Marketing Permission for ALS in South Korea**

Mitsubishi Tanabe Pharma Corporation (Head Office: Osaka; President & Representative Director: Masayuki Mitsuka) announced that its consolidated subsidiary Mitsubishi Tanabe Pharma Korea (Head Office: Seoul, Korea; President & Representative Director: Kazuharu Matsuoka) has received import and marketing permission for RADICUT<sup>®</sup> inj. 30mg and RADICUT<sup>®</sup> Infusion inj. 30mg (generic name: edaravone) for an indication of progress delay of functional disorder in patients with amyotrophic lateral sclerosis (ALS).

Radicut<sup>®</sup> is a free radical scavenger that was discovered by Mitsubishi Tanabe Pharma. In Japan, it is being marketed with indications of (1)Improvement of neurological symptoms, disorder of activities of daily living, and functional disorder associated with acute ischaemic stroke , and (2) Inhibition on progression of functional disorder in patients with amyotrophic lateral sclerosis (ALS). The additional indication of inhibition on progression of functional disorder in patients with ALS was approved in June 2015, and by the end of November Radicut<sup>®</sup> had been administered to more than 800 patients with ALS.

Through this acquisition of permission for Radicut<sup>®</sup>, Mitsubishi Tanabe Pharma expects to expand the options for ALS treatment in South Korea.

《(For Details, Contact the Following Section)》  
Corporate Communications Department  
Tel +81-6-6205-5211